Busardò Francesco Paolo, Carlier Jeremy, Giorgetti Raffaele, Tagliabracci Adriano, Pacifici Roberta, Gottardi Massimo, Pichini Simona
Section of Legal Medicine, Università Politecnica Delle Marche, Ancona, Italy.
Unit of Forensic Toxicology, Università la Sapienza, Rome, Italy.
Front Chem. 2019 Apr 2;7:184. doi: 10.3389/fchem.2019.00184. eCollection 2019.
Recently, synthetic opioid-related overdose fatalities, led by illicitly manufactured fentanyl and analogs, increased at an alarming rate, posing a global public health threat. New synthetic fentanyl analogs have been constantly emerging onto the drug marked for the last few years, to circumvent the laws and avoid analytical detection. Analytical methods need to be regularly updated to keep up with the new trends. In this study, we aimed to develop a new method for detecting the newest fentanyl analogs with a high sensitivity, in whole blood, urine, and hair. The method is intended to provide to clinical and forensic toxicologists a tool for documenting consumption. We developed a comprehensive ultra-high-performance liquid chromatography-tandem mass spectrometry method for quantifying fentanyl and 22 analogs and metabolites. Urine samples were simply diluted before injection; a liquid-liquid extraction was performed for blood testing; and a solid phase extraction was performed in hair. The chromatographic separation was short (8 min). The method was validated with a high sensitivity; limits of quantifications ranged from 2 to 6 ng/L in blood and urine, and from 11 to 21 pg/g in hair. The suitability of the method was tested with 42 postmortem blood, urine, or hair specimens from 27 fatalities in which fentanyl analogs were involved. Average blood concentrations (±SD) were 7.84 ± 7.21 and 30.0 ± 18.0 μg/L for cyclopropylfentanyl and cyclopropyl norfentanyl, respectively ( = 8), 4.08 ± 2.30 μg/L for methoxyacetylfentanyl, ( = 4), 40.2 ± 38.6 and 44.5 ± 21.1 μg/L for acetylfentanyl and acetyl norfentanyl, respectively ( = 3), 33.7 and 7.17 μg/L for fentanyl and norfentanyl, respectively ( = 1), 3.60 and 0.90 μg/L for furanylfentanyl and furanyl norfentanyl, respectively ( = 1), 0.67 μg/L for sufentanil ( = 1), and 3.13 ± 2.37 μg/L for 4-ANPP ( = 9). Average urine concentrations were 47.7 ± 39.3 and 417 ± 296 μg/L for cyclopropylfentanyl and cyclopropyl norfentanyl, respectively ( = 11), 995 ± 908 μg/L for methoxyacetylfentanyl, ( = 3), 1,874 ± 1,710 and 6,582 ± 3,252 μg/L for acetylfentanyl and acetyl norfentanyl, respectively ( = 5), 146 ± 318 and 300 ± 710 μg/L for fentanyl ( = 5) and norfentanyl ( = 6), respectively, 84.0 and 23.0 μg/L for furanylfentanyl and furanyl norfentanyl, respectively ( = 1), and 50.5 ± 50.9 μg/L for 4-ANPP ( = 10). Average hair concentrations were 2,670 ± 184 and 82.1 ± 94.7 ng/g for fentanyl and norfentanyl, respectively ( = 2), and 10.8 ± 0.57 ng/g for 4-ANPP ( = 2).
最近,以非法制造的芬太尼及其类似物为首的合成阿片类药物过量致死事件以惊人的速度增加,对全球公共卫生构成威胁。在过去几年中,新型合成芬太尼类似物不断涌入毒品市场,以规避法律并避免分析检测。分析方法需要定期更新以跟上新趋势。在本研究中,我们旨在开发一种新方法,以高灵敏度检测全血、尿液和毛发中的最新芬太尼类似物。该方法旨在为临床和法医毒理学家提供一种记录药物使用情况的工具。我们开发了一种全面的超高效液相色谱-串联质谱法,用于定量芬太尼及22种类似物和代谢物。尿液样品在进样前只需稀释;血液检测采用液-液萃取;毛发检测采用固相萃取。色谱分离时间短(8分钟)。该方法经过高灵敏度验证;血液和尿液中的定量限范围为2至6 ng/L,毛发中的定量限范围为11至21 pg/g。该方法的适用性通过来自27例涉及芬太尼类似物死亡案例的42份死后血液、尿液或毛发标本进行测试。环丙基芬太尼和环丙基去甲芬太尼的平均血液浓度(±标准差)分别为7.84±7.21和30.0±18.0 μg/L(n = 8),甲氧基乙酰芬太尼为4.08±2.30 μg/L(n = 4),乙酰芬太尼和乙酰去甲芬太尼分别为40.2±38.6和44.5±21.1 μg/L(n = 3),芬太尼和去甲芬太尼分别为33.7和7.17 μg/L(n = 1),呋喃基芬太尼和呋喃基去甲芬太尼分别为3.60和0.90 μg/L(n = 1),舒芬太尼为0.67 μg/L(n = 1),4-ANPP为3.13±2.37 μg/L(n = 9)。环丙基芬太尼和环丙基去甲芬太尼的平均尿液浓度分别为47.7±39.3和417±296 μg/L(n = 11),甲氧基乙酰芬太尼为995±908 μg/L(n = 3),乙酰芬太尼和乙酰去甲芬太尼分别为1,874±1,710和6,582±3,252 μg/L(n = 5),芬太尼(n = 5)和去甲芬太尼(n = 6)分别为146±318和300±710 μg/L,呋喃基芬太尼和呋喃基去甲芬太尼分别为84.0和23.0 μg/L(n = 1),4-ANPP为50.5±50.9 μg/L(n = 10)。芬太尼和去甲芬太尼的平均毛发浓度分别为2,670±184和82.1±94.7 ng/g(n = 2),4-ANPP为10.8±0.57 ng/g(n = 2)。